RecruitingNot ApplicableNCT05748990

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia


Sponsor

Centre for Addiction and Mental Health

Enrollment

20 participants

Start Date

Apr 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes. Additionally, almost half of the patients with SCZ are obese, the prevalence of type 2 diabetes is 3-6 times higher, and life expectancy is lower by 15-20 years compared to the general population. This is relevant as metabolic syndrome and diabetes are both associated with worse cognition among SCZ patients. Recent work studying the relationships between metabolic health and cognition has encouraged a new way of thinking about SCZ as both a metabolic and cognitive disorder. Brain insulin is involved in several processes relevant to SCZ, and abnormal brain insulin action may help explain both cognitive and metabolic abnormalities in patients with SCZ, but this has not been examined previously. Glucose uptake in several brain regions relevant to SCZ has been shown to be partially dependent on insulin. Therefore, in this study, the researchers will measure glucose uptake in the brain using an 18F-fluorodeoxyglucose (\[18F\]-FDG) positron emission tomography (PET) scan after an intranasal insulin stimulus, and will compare this measure between patients with SCZ and healthy controls.


Eligibility

Min Age: 17 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating whether the brain's abnormal response to insulin (the hormone that regulates blood sugar) is a cause of the cognitive and metabolic problems seen in people with schizophrenia spectrum disorders, compared to healthy individuals. **You may be eligible if...** - You are between 17 and 45 years old - You have a first-episode schizophrenia spectrum disorder (including schizophrenia, schizoaffective disorder, bipolar I or II with psychosis, or related conditions) and are on antipsychotic medication, OR - You are a healthy individual willing to serve as a control participant - Your BMI is 27 or under **You may NOT be eligible if...** - You have diabetes, pre-diabetes, or abnormal blood sugar on screening - You have a moderate to severe substance use disorder - You have a pacemaker, metal implants, or other MRI contraindications - You have significant liver or kidney disease - You are pregnant or breastfeeding - You are currently taking medications for weight loss, blood pressure, or blood sugar Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIntranasal insulin

160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.

DRUGPlacebo

0.9% saline is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.


Locations(1)

Centre for Addiction and Mental Health

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05748990


Related Trials